Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00220636
Status:
COMPLETED
Last Update Posted:
2016-05-26
First Post:
2005-09-21
Brief Title:
Abilify as an Adjunctive Treatment for Refractory Depression
Sponsor:
St Lukes-Roosevelt Hospital Center
Organization:
St Lukes-Roosevelt Hospital Center
Study Overview
Official Title:
Abilify Aripiprazole as an Adjunctive Treatment for Refractory Unipolar Depression
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of the effectiveness of adding Abilify aripiprazole an atypical antipsychotic medication to ongoing selective serotonin reuptake inhibitor SSRI antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone It is hypothesized that patients functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication
Detailed Description:
This is a pilot study of the effectiveness of adding Abilify aripiprazole an atypical antipsychotic medication to ongoing selective serotonin reuptake inhibitor SSRI antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone Fifteen subjects will be given aripiprazole in a flexible dosing schedule and followed for 12 weeks while continuing their ongoing SSRI medication Assessments of depressive symptoms overall functioning social functioning and side effects will be completed It is hypothesized that patients functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None